Loading
Life sciences · Journal article
Endocrinologia · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an established therapeutic class for the management of type 2 diabetes mellitus and obesity. Their increasing use among women of reproductive age has raised important concerns regarding their potential impact on fertility, preconception care, and safety during pregnancy. Current evidence suggests that GLP-1RAs may exert beneficial effects on ovulatory function, menstrual regularity, and the inflammatory milieu, particularly in women with insulin resistance and hyperandrogenism. Potential effects on endometrial function, implantation, and maternal–fetal immune tolerance have also been discussed. Nevertheless, the available evidence regarding exposure during pregnancy remains limited. Findings from animal studies have raised concerns about fetal development, particularly with respect to skeletal ossification, skin development, and neurogenesis, whereas observational studies in humans appear somewhat reassuring regarding the risk of major congenital malformations, although they do not allow for definitive safety conclusions. Consequently, GLP-1RAs are not recommended during pregnancy, and women with reproductive intentions should receive individualized preconception counseling and guidance regarding an appropriate treatment discontinuation period prior to conception.